BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Phase 1 Completed R-Pharm Memorial Sloan Kettering Cancer Center · collab National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors that have not responded to previous therapy.

Timeline

Start: 1999-07
Primary completion: 2002-10
Completion: 2002-10

Publications

Results Aghajanian C, Burris HA 3rd, Jones S, Spriggs DR, Cohen MB, Peck R, Sabbatini P, Hensley ML, Greco FA, Dupont J, O'Connor OA. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2007 Mar 20;25(9):1082-8. doi: 10.1200/JCO.2006.08.7304. Epub 2007 Jan 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ixabepilone	Small molecule	40 mg/m2	Intravenous
Subject	Ixabepilone	Small molecule	50 mg/m2	Intravenous

BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Summary

Timeline

Publications

Drugs

Indications